Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Carcinoma × brigatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Large Cell 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Pemetrexed 3 Carboplatin 3 durvalumab 2 Cisplatin 2 tremelimumab 1 repotrectinib 1 pralsetinib 1 osimertinib 1 brigatinib 1 atezolizumab 1 Surgical Procedures, Operative 1 Paclitaxel 1 Mitomycin 1 Gemcitabine 1 Crizotinib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡